Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I could not count how many times. But it has always been a 52 week low bouncer since I have played it. Only difference now is volume is more resulting from the OS growing more. BETS
LOL I am saying that would be Ideal and if the low get tested it should go lower then 12 IMO so trips are not far from 12 just saying it could be possible. BETS
I agree BETS is a 52 week low bounce play and that is it IMO BETS
Yes sellers always create new 52 week lows and 52 week lows always have bounces. Pretty simple math. BETS
Actually IMO it is better to not sell at all but hey I now beggars can't be chooser. Or can they be? Only thing BETS is known for is bouncing off of 52 week lows. BETS
Yes I owned millions at over 2 cents and could not believe it would ever sink in PPS then it dipped big in a couple days and nothing could be done. The PPS of BETS has gone down down and downer for as long as I can remember. The only thing that brings life and volume to BETS is new 52 week low. So everyone better hope a new low gets tested IMO. BETS
So you are saying they are pumping with news and dumping into the news? Imagine that? I would have never thought. I am glad you are so savvy and appreciate the quality advice! BETS
Well when it gets there I won't rub it in. As to me it is pretty obvious it is coming. Unless you have some catalyst I don't know about? BETS
Really? Why? If all the other news could not why would that news? It seems it would only be followed by an RS after Summits reserve is gone. So I am sure traders are taking this all into consideration so not sure if that AS reduction news will be any great catalyst. The OS of BETS has continually grown for 1 year. AS a little over a year ago the float was 10 million shares and OS was 40 million. So now OS is over 500 million one could ask why would dilution stop now? BETS
No doubt. To much risk buying at .0015 with the current volume and low demand. Not to mention news can't even push it. Looking to load 52 week low and hopefully get a bounce on some fluff news of AS reduction would be a possibility. BETS
Yes however I would rather be loading here now. The other has not bottomed out yet. This range is prime for OCLG and the OS and float are way better. OCG will trade way thinner and revenues and debt comparison are way better with OCLG IMO $OCLG
It bounced off of .0015 before but demand and volume seems low so I am sure it will at least test the 52 week low and sooner then later IMO but we will see. I actually feel testing the 52 week low will be the only thing that may revive it. BETS
Few things missing in that DD. One if them being they had a net loss of over $700K last year. So we have no clue until future filings come how that has changed if any at all. Not to mention the value of all this decrease every single share they dilute into the market. Summit already filed a form to own up to 4.9% of the OS and any point right? So nothing is stopping Summit from converting the old debt since forms are already filed to do so. We would never know unless they get more then 4.9% and hold them. Never the less there have seemed to be many catalyst for BETS lately yet volume and demand has actually decreased and that is not good IMO. I feel if 52 week low gets tested which IMO is going to happen then demand may come back. But I feel new 52 week low will come and possible triple subs. We will see. BETS
New 52 week low coming IMO and that would be the time to look to load if any IMO. I don't think it will hit triple sub penny but it could IMO. BETS
Seems to many doom and gloomers and not enough optimism for what is really happening. Anytime someone is selling and a PPS/Markey cap is affordable it is prime time to take advantage. Once seller is done then these prices are gone and never to be seen again. So opportunity is a knocking IMO. $OCLG
Well your opinion is yours as mine is mine! Thanks for your interest in $OCLG!
I did a small buy myself today. It is hard not to buy here. I had said I was only going in so much but have already exceeded that. I figure this is a no brainer to park my money here IMO. $OCLG
Things heating up over here at OCLG. Nice volume! Nice Accumulation!! Nice News!! Awesome Revenues!! Low Share Structure!! Catalyst on the way!! $OCLG
I agree now is the time. I was fully loaded last week but had to buy a few more today!! $OCLG
Your welcome Mr Fox $OCLG
Well good accumulation either way. It will soon deliver $OCLG
Gap got filled at least. $OCLG
OCLG news is solid today:
OCLG Provides Update on Its Proposed Acquisition of a Leading Medical Products CompanyFont size: A | A | A
8:45 AM ET 3/16/15 | Marketwired
Oncologix Tech Inc. (OTC PINK: OCLG), a fully reporting, diversified medical holding company with operating units in medical devices, medical products and healthcare services, announces update on proposed acquisition.
OCLG previously announced that, pursuant to an executed Letter of Intent, the company proposed acquisition of a leading Home Medical/Durable Medical and both parties have agreed to use their best efforts to complete the respective asset verifications, financial due diligence and negotiate in good faith to enter into a definitive Stock Purchase Agreement.
Wayne Erwin, the CEO of OCLG stated, "We continue to make significant progress with the closing of the acquisition. We were required to adjust the funding strategy to avoid excessive shareholder dilution, complete the acquired entity's financial audit and, lastly, we are now in the final underwriting and due diligence process required by our new lending partner."
The company has two (2) primary objectives when reviewing strategic acquisitions in medical products and distribution. The acquisitions must:
1. Accelerate our company's growth with a core platform for medical product sales and distribution across the U.S. 2. Exhibit a solid track record of revenue growth, healthy earnings and free cash flow.
Erwin continued, "This acquisition certainly meets our criteria and post-closing, and would position OCLG with a total of $15.6 mm in annualized revenues, positive earnings and operational cash flows. We also are in the initial phases of our due diligence with an additional Home Medical company that has $10.2 million in annual revenues. The acquisitions along with our operating subsidiaries in health services and medical devices will support our strategic objective to achieve $35 million in annual revenues and $3.5 million of positive EBITA in FY 2015."
OCLG will issue a further news release as soon as additional details are available regarding the proposed acquisition.
Reader Advisory The proposed completion of the acquisition is subject to a number of conditions, including but not limited to, Board of Directors acceptance, financial due diligence, underwriting for capital lending and the company cannot close any transaction until the required approvals are obtained. There can be no assurance that this acquisition will be completed as proposed or at all.
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking information in this press release includes, but is not limited to, statements with respect to timing and completion of the due diligence relating to the Acquisition, the entering into of the Formal Agreement and the completion of the conditions precedent to the Acquisition. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: general economic conditions in the United States and globally; industry conditions, including favorable results in the medical products competitive bid process, governmental regulation of medical reimbursements; unanticipated operating events or performance which can reduce product sales and distribution; failure to obtain industry partner and other third party consents and approvals, and the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; stock market volatility; competition for, among other things, capital, skilled personnel and supplies; incorrect assessments of the value of acquisition; failure to realize the anticipated benefits of acquisitions and dispositions; and the other factors. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
About Oncologix Tech Oncologix is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Health Care Services, and sells and distributes Durable and Home Medical Equipment. For its clients, Oncologix provides FDA approved medical devices, state licensed healthcare services, and medical products and technologies. For its shareholders, Oncologix operates profitable divisions that build, maintain and nourish all shareholder value. The Company's corporate mission is to be the best small cap medical holding company in North America.
CONTACT INFORMATION
Wayne Erwin
Chairman and CEO
INVESTOR RELATIONS
Synergy Business Consultants, LLC.
(727) 491-3911
The news is out on OCLG just not on Ihub $OCLG
OCLG Provides Update on Its Proposed Acquisition of a Leading Medical Products CompanyFont size: A | A | A
8:45 AM ET 3/16/15 | Marketwired
Oncologix Tech Inc. (OTC PINK: OCLG), a fully reporting, diversified medical holding company with operating units in medical devices, medical products and healthcare services, announces update on proposed acquisition.
OCLG previously announced that, pursuant to an executed Letter of Intent, the company proposed acquisition of a leading Home Medical/Durable Medical and both parties have agreed to use their best efforts to complete the respective asset verifications, financial due diligence and negotiate in good faith to enter into a definitive Stock Purchase Agreement.
Wayne Erwin, the CEO of OCLG stated, "We continue to make significant progress with the closing of the acquisition. We were required to adjust the funding strategy to avoid excessive shareholder dilution, complete the acquired entity's financial audit and, lastly, we are now in the final underwriting and due diligence process required by our new lending partner."
The company has two (2) primary objectives when reviewing strategic acquisitions in medical products and distribution. The acquisitions must:
1. Accelerate our company's growth with a core platform for medical product sales and distribution across the U.S. 2. Exhibit a solid track record of revenue growth, healthy earnings and free cash flow.
Erwin continued, "This acquisition certainly meets our criteria and post-closing, and would position OCLG with a total of $15.6 mm in annualized revenues, positive earnings and operational cash flows. We also are in the initial phases of our due diligence with an additional Home Medical company that has $10.2 million in annual revenues. The acquisitions along with our operating subsidiaries in health services and medical devices will support our strategic objective to achieve $35 million in annual revenues and $3.5 million of positive EBITA in FY 2015."
OCLG will issue a further news release as soon as additional details are available regarding the proposed acquisition.
Reader Advisory The proposed completion of the acquisition is subject to a number of conditions, including but not limited to, Board of Directors acceptance, financial due diligence, underwriting for capital lending and the company cannot close any transaction until the required approvals are obtained. There can be no assurance that this acquisition will be completed as proposed or at all.
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking information in this press release includes, but is not limited to, statements with respect to timing and completion of the due diligence relating to the Acquisition, the entering into of the Formal Agreement and the completion of the conditions precedent to the Acquisition. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: general economic conditions in the United States and globally; industry conditions, including favorable results in the medical products competitive bid process, governmental regulation of medical reimbursements; unanticipated operating events or performance which can reduce product sales and distribution; failure to obtain industry partner and other third party consents and approvals, and the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; stock market volatility; competition for, among other things, capital, skilled personnel and supplies; incorrect assessments of the value of acquisition; failure to realize the anticipated benefits of acquisitions and dispositions; and the other factors. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
About Oncologix Tech Oncologix is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Health Care Services, and sells and distributes Durable and Home Medical Equipment. For its clients, Oncologix provides FDA approved medical devices, state licensed healthcare services, and medical products and technologies. For its shareholders, Oncologix operates profitable divisions that build, maintain and nourish all shareholder value. The Company's corporate mission is to be the best small cap medical holding company in North America.
CONTACT INFORMATION
Wayne Erwin
Chairman and CEO
INVESTOR RELATIONS
Synergy Business Consultants, LLC.
(727) 491-3911
OCLG news is big Nice! $OCLG
OCLG news nice today!! $OCLG
OCLG nice news today! $OCLG
That OCLG chart is looking Amazing! $OCLG
$OCLG Sexy
Many of us reached out for an update and OCLG gave it to us. That was solid that the company cares that much about its shareholders IMO!! $OCLG
OCLG News today Huge!! $OCLG
OCLG Provides Update on Its Proposed Acquisition of a Leading Medical Products CompanyFont size: A | A | A
8:45 AM ET 3/16/15 | Marketwired
Oncologix Tech Inc. (OTC PINK: OCLG), a fully reporting, diversified medical holding company with operating units in medical devices, medical products and healthcare services, announces update on proposed acquisition.
OCLG previously announced that, pursuant to an executed Letter of Intent, the company proposed acquisition of a leading Home Medical/Durable Medical and both parties have agreed to use their best efforts to complete the respective asset verifications, financial due diligence and negotiate in good faith to enter into a definitive Stock Purchase Agreement.
Wayne Erwin, the CEO of OCLG stated, "We continue to make significant progress with the closing of the acquisition. We were required to adjust the funding strategy to avoid excessive shareholder dilution, complete the acquired entity's financial audit and, lastly, we are now in the final underwriting and due diligence process required by our new lending partner."
The company has two (2) primary objectives when reviewing strategic acquisitions in medical products and distribution. The acquisitions must:
1. Accelerate our company's growth with a core platform for medical product sales and distribution across the U.S. 2. Exhibit a solid track record of revenue growth, healthy earnings and free cash flow.
Erwin continued, "This acquisition certainly meets our criteria and post-closing, and would position OCLG with a total of $15.6 mm in annualized revenues, positive earnings and operational cash flows. We also are in the initial phases of our due diligence with an additional Home Medical company that has $10.2 million in annual revenues. The acquisitions along with our operating subsidiaries in health services and medical devices will support our strategic objective to achieve $35 million in annual revenues and $3.5 million of positive EBITA in FY 2015."
OCLG will issue a further news release as soon as additional details are available regarding the proposed acquisition.
Reader Advisory The proposed completion of the acquisition is subject to a number of conditions, including but not limited to, Board of Directors acceptance, financial due diligence, underwriting for capital lending and the company cannot close any transaction until the required approvals are obtained. There can be no assurance that this acquisition will be completed as proposed or at all.
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking information in this press release includes, but is not limited to, statements with respect to timing and completion of the due diligence relating to the Acquisition, the entering into of the Formal Agreement and the completion of the conditions precedent to the Acquisition. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: general economic conditions in the United States and globally; industry conditions, including favorable results in the medical products competitive bid process, governmental regulation of medical reimbursements; unanticipated operating events or performance which can reduce product sales and distribution; failure to obtain industry partner and other third party consents and approvals, and the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; stock market volatility; competition for, among other things, capital, skilled personnel and supplies; incorrect assessments of the value of acquisition; failure to realize the anticipated benefits of acquisitions and dispositions; and the other factors. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
About Oncologix Tech Oncologix is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Health Care Services, and sells and distributes Durable and Home Medical Equipment. For its clients, Oncologix provides FDA approved medical devices, state licensed healthcare services, and medical products and technologies. For its shareholders, Oncologix operates profitable divisions that build, maintain and nourish all shareholder value. The Company's corporate mission is to be the best small cap medical holding company in North America.
CONTACT INFORMATION
Wayne Erwin
Chairman and CEO
INVESTOR RELATIONS
Synergy Business Consultants, LLC.
(727) 491-3911
For sure once Fins come we will be off to the races big IMO!! $OCLG
OCLG todays news BREAKOUT!!
OCLG Provides Update on Its Proposed Acquisition of a Leading Medical Products CompanyFont size: A | A | A
8:45 AM ET 3/16/15 | Marketwired
Oncologix Tech Inc. (OTC PINK: OCLG), a fully reporting, diversified medical holding company with operating units in medical devices, medical products and healthcare services, announces update on proposed acquisition.
OCLG previously announced that, pursuant to an executed Letter of Intent, the company proposed acquisition of a leading Home Medical/Durable Medical and both parties have agreed to use their best efforts to complete the respective asset verifications, financial due diligence and negotiate in good faith to enter into a definitive Stock Purchase Agreement.
Wayne Erwin, the CEO of OCLG stated, "We continue to make significant progress with the closing of the acquisition. We were required to adjust the funding strategy to avoid excessive shareholder dilution, complete the acquired entity's financial audit and, lastly, we are now in the final underwriting and due diligence process required by our new lending partner."
The company has two (2) primary objectives when reviewing strategic acquisitions in medical products and distribution. The acquisitions must:
1. Accelerate our company's growth with a core platform for medical product sales and distribution across the U.S. 2. Exhibit a solid track record of revenue growth, healthy earnings and free cash flow.
Erwin continued, "This acquisition certainly meets our criteria and post-closing, and would position OCLG with a total of $15.6 mm in annualized revenues, positive earnings and operational cash flows. We also are in the initial phases of our due diligence with an additional Home Medical company that has $10.2 million in annual revenues. The acquisitions along with our operating subsidiaries in health services and medical devices will support our strategic objective to achieve $35 million in annual revenues and $3.5 million of positive EBITA in FY 2015."
OCLG will issue a further news release as soon as additional details are available regarding the proposed acquisition.
Reader Advisory The proposed completion of the acquisition is subject to a number of conditions, including but not limited to, Board of Directors acceptance, financial due diligence, underwriting for capital lending and the company cannot close any transaction until the required approvals are obtained. There can be no assurance that this acquisition will be completed as proposed or at all.
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking information in this press release includes, but is not limited to, statements with respect to timing and completion of the due diligence relating to the Acquisition, the entering into of the Formal Agreement and the completion of the conditions precedent to the Acquisition. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: general economic conditions in the United States and globally; industry conditions, including favorable results in the medical products competitive bid process, governmental regulation of medical reimbursements; unanticipated operating events or performance which can reduce product sales and distribution; failure to obtain industry partner and other third party consents and approvals, and the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; stock market volatility; competition for, among other things, capital, skilled personnel and supplies; incorrect assessments of the value of acquisition; failure to realize the anticipated benefits of acquisitions and dispositions; and the other factors. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
About Oncologix Tech Oncologix is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Health Care Services, and sells and distributes Durable and Home Medical Equipment. For its clients, Oncologix provides FDA approved medical devices, state licensed healthcare services, and medical products and technologies. For its shareholders, Oncologix operates profitable divisions that build, maintain and nourish all shareholder value. The Company's corporate mission is to be the best small cap medical holding company in North America.
CONTACT INFORMATION
Wayne Erwin
Chairman and CEO
INVESTOR RELATIONS
Synergy Business Consultants, LLC.
(727) 491-3911
OCLG todays huge news below!!
OCLG Provides Update on Its Proposed Acquisition of a Leading Medical Products CompanyFont size: A | A | A
8:45 AM ET 3/16/15 | Marketwired
Oncologix Tech Inc. (OTC PINK: OCLG), a fully reporting, diversified medical holding company with operating units in medical devices, medical products and healthcare services, announces update on proposed acquisition.
OCLG previously announced that, pursuant to an executed Letter of Intent, the company proposed acquisition of a leading Home Medical/Durable Medical and both parties have agreed to use their best efforts to complete the respective asset verifications, financial due diligence and negotiate in good faith to enter into a definitive Stock Purchase Agreement.
Wayne Erwin, the CEO of OCLG stated, "We continue to make significant progress with the closing of the acquisition. We were required to adjust the funding strategy to avoid excessive shareholder dilution, complete the acquired entity's financial audit and, lastly, we are now in the final underwriting and due diligence process required by our new lending partner."
The company has two (2) primary objectives when reviewing strategic acquisitions in medical products and distribution. The acquisitions must:
1. Accelerate our company's growth with a core platform for medical product sales and distribution across the U.S. 2. Exhibit a solid track record of revenue growth, healthy earnings and free cash flow.
Erwin continued, "This acquisition certainly meets our criteria and post-closing, and would position OCLG with a total of $15.6 mm in annualized revenues, positive earnings and operational cash flows. We also are in the initial phases of our due diligence with an additional Home Medical company that has $10.2 million in annual revenues. The acquisitions along with our operating subsidiaries in health services and medical devices will support our strategic objective to achieve $35 million in annual revenues and $3.5 million of positive EBITA in FY 2015."
OCLG will issue a further news release as soon as additional details are available regarding the proposed acquisition.
Reader Advisory The proposed completion of the acquisition is subject to a number of conditions, including but not limited to, Board of Directors acceptance, financial due diligence, underwriting for capital lending and the company cannot close any transaction until the required approvals are obtained. There can be no assurance that this acquisition will be completed as proposed or at all.
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking information in this press release includes, but is not limited to, statements with respect to timing and completion of the due diligence relating to the Acquisition, the entering into of the Formal Agreement and the completion of the conditions precedent to the Acquisition. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: general economic conditions in the United States and globally; industry conditions, including favorable results in the medical products competitive bid process, governmental regulation of medical reimbursements; unanticipated operating events or performance which can reduce product sales and distribution; failure to obtain industry partner and other third party consents and approvals, and the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; stock market volatility; competition for, among other things, capital, skilled personnel and supplies; incorrect assessments of the value of acquisition; failure to realize the anticipated benefits of acquisitions and dispositions; and the other factors. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
About Oncologix Tech Oncologix is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Health Care Services, and sells and distributes Durable and Home Medical Equipment. For its clients, Oncologix provides FDA approved medical devices, state licensed healthcare services, and medical products and technologies. For its shareholders, Oncologix operates profitable divisions that build, maintain and nourish all shareholder value. The Company's corporate mission is to be the best small cap medical holding company in North America.
CONTACT INFORMATION
Wayne Erwin
Chairman and CEO
INVESTOR RELATIONS
Synergy Business Consultants, LLC.
(727) 491-3911
73s done ask is insane thin!! Nice solid volume slow and steady! $OCLG
OCLG has big news out today. Very solid volume day. Huge revenues coming and and financials be here is a couple weeks!! $OCLG
OCLG Sexy Breakout!! $OLCG
OLCG moving big large volume huge news!! $OCLG
Erwin continued, "This acquisition certainly meets our criteria and post-closing, and would position OCLG with a total of $15.6 mm in annualized revenues, positive earnings and operational cash flows. We also are in the initial phases of our due diligence with an additional Home Medical company that has $10.2 million in annual revenues. The acquisitions along with our operating subsidiaries in health services and medical devices will support our strategic objective to achieve $35 million in annual revenues and $3.5 million of positive EBITA in FY 2015."
OCLG Big News Breakout!! $OLCG
OLCG moving big large volume huge news!! $OCLG
Erwin continued, "This acquisition certainly meets our criteria and post-closing, and would position OCLG with a total of $15.6 mm in annualized revenues, positive earnings and operational cash flows. We also are in the initial phases of our due diligence with an additional Home Medical company that has $10.2 million in annual revenues. The acquisitions along with our operating subsidiaries in health services and medical devices will support our strategic objective to achieve $35 million in annual revenues and $3.5 million of positive EBITA in FY 2015."
$OCLG News BREAKOUT!! $OCLG